/Companies

TendoNova

Atlanta, US · Founded 2017 · 4 known investors

Find your way into TendoNova

Sign up to see every warm intro you have to TendoNova

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the TendoNova team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

TendoNova develops microinvasive medical technology, including its Ocelot Nano device, to treat chronic tendon pain in patients. The company targets clinical use for patients with tendon injuries, including athletes.

Founders & leadership

ICIan Campbell
Ian CampbellInvestor & Board MemberIan Campbell holds an MS in Aerospace Engineering from Georgia Tech and has co-founded and exited two prior high-tech ventures: NextInput (MEMS and sensor technology, acquired by Qorvo) and OnScale (cloud-based engineering simulation, acquired by Ansys). He currently serves as an investor and advisor to multiple deep technology companies.
MS
Mark SamuelsNamed on SEC filing
LM
Louis MaliceNamed on SEC filing
LG
Luka GrujicNamed on SEC filing
SK
Shawna KhouriNamed on SEC filing
BR
Brett RogersNamed on SEC filing

Board

JC
Jeff ClarkBoard director
JS
Jonathan ShawBoard director
PH
Peter HaalandBoard directorGeneral Partner at InnerProduct Partners

Investors · 4

Reported raises · per SEC filings

Form D private placements

$3.8M disclosed across 7 rounds · 2019–2024

▶$270KraisedAug 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeff ClarkDirector
  • Jonathan ShawDirector
  • Ian CampbellExecutive Officer, Director
  • Peter HaalandDirector
Offering amount
$400K
Amount sold
$270K
First sale
Jun 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$762KraisedMay 2024 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan ShawDirector
  • Jeff ClarkDirector
  • Mark SamuelsExecutive Officer, Director
  • Ian CampbellDirector
  • Peter HaalandDirector
Offering amount
$1.1M
Amount sold
$762K
First sale
Feb 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$250KraisedJan 2024 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shawna KhouriDirector
  • Mark SamuelsExecutive Officer, Director
  • Jonathan ShawDirector
  • Luka GrujicDirector
  • Peter HaalandDirector
  • Brett RogersDirector
  • Louis MaliceDirector
Offering amount
$500K
Amount sold
$250K
First sale
Nov 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$300KraisedOct 2023 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Luka GrujicDirector
  • Jonathan ShawDirector
  • Peter HaalandDirector
  • Louis MaliceDirector
  • Shawna KhouriDirector
  • Brett RogersDirector
  • Mark SamuelsExecutive Officer, Director
Offering amount
$300K
Amount sold
$300K
First sale
Jul 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$440KraisedDec 2022 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Luka GrujicDirector
  • Shawna KhouriDirector
  • Jonathan ShawDirector
  • Louis MaliceDirector
  • Peter HaalandDirector
  • Brett RogersDirector
  • Mark SamuelsExecutive Officer, Director
Offering amount
$700K
Amount sold
$440K
First sale
Jul 2022
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$446.3KraisedAug 2022 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan ShawDirector
  • Shawna KhouriDirector
  • Luka GrujicDirector
  • Brett RogersDirector
  • Louis MaliceDirector
  • Mark SamuelsExecutive Officer, Director
  • Peter HaalandDirector
Offering amount
$2M
Amount sold
$446.3K
First sale
Sep 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.4MraisedFeb 2021 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark SamuelsExecutive Officer
  • Peter HaalandDirector
  • Jonathan ShawExecutive Officer, Director
  • Louis MaliceDirector
  • Luka GrujicDirector
  • Shawna KhouriDirector
  • Brett RogersDirector
Offering amount
$1.5M
Amount sold
$1.4M
Minimum investment
$10K
Proceeds to insiders
$50K
First sale
Apr 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

Companies working in the same space as TendoNova.

In the news

Frequently asked questions

What does TendoNova do?
TendoNova develops microinvasive medical technology, including its Ocelot Nano device, to treat chronic tendon pain in patients. The company targets clinical use for patients with tendon injuries, including athletes.
Who are TendoNova's investors?
TendoNova's investors include Arieal Southeast Angel Partners, Walnut Venture Associates, InnerProduct Partners, VentureSouth.
How much funding has TendoNova raised?
TendoNova has disclosed $3.8M raised across 7 rounds.
Where is TendoNova headquartered?
TendoNova is headquartered in Atlanta, US.